{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:07:16Z","timestamp":1791295636015,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2005,5,23]],"date-time":"2005-05-23T00:00:00Z","timestamp":1116806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Internal Medicine"],"published-print":{"date-parts":[[2005,6]]},"abstract":"<jats:title>Abstract.<\/jats:title><jats:p><jats:bold>Objectives.\u2002<\/jats:bold> Rituximab (RIT) is a monoclonal anti\u2010CD20 antibody, which depletes B\u2010lymphocytes but not plasma cells. RIT is used for treatment of B\u2010cell lymphomas, but has also shown beneficial effects in autoimmune diseases. In this case series RIT was used in anti\u2010neutrophil cytoplasmic antibody (ANCA)\u2010positive vasculitis.<\/jats:p><jats:p><jats:bold>Design.\u2002<\/jats:bold> Case series with a structured follow\u2010up of treated patients.<\/jats:p><jats:p><jats:bold>Setting.\u2002<\/jats:bold> Departments of Nephrology and Rheumatology of a university hospital.<\/jats:p><jats:p><jats:bold>Subjects.\u2002<\/jats:bold> Two women with myeloperoxidase\u2010ANCA\u2010positive microscopic polyangiitis and seven patients (five men and two women) with proteinase 3\u2010ANCA\u2010positive Wegener's granulomatosis. All patients were resistant to conventional therapy or had relapsed repeatedly after cessation of cyclophosphamide (Cyc).<\/jats:p><jats:p><jats:bold>Interventions.\u2002<\/jats:bold> The cases were treated with intravenous infusions of RIT once a week two times (three cases) or four times (six cases). To prevent formation of antibodies to RIT, mycophenolate mofetil (five patients), azathioprine (one patient), or a short course of Cyc (two patients) were added or allowed to continue.<\/jats:p><jats:p><jats:bold>Main outcome measures.\u2002<\/jats:bold> Remission at 6\u2003months assessed with Birmingham vasculitis activity score. The cases were followed 6\u201324\u2003months and relapse rate was also noted.<\/jats:p><jats:p><jats:bold>Results.\u2002<\/jats:bold> Eight of nine patients responded completely and one case responded partially. Pulmonary X\u2010ray improved (four cases), progress of lower extremity gangrene stopped (one case), remission of neuropathy was stable (one patient), renal vasculitis went into remission (two cases), and severe musculoskeletal pain improved (one case). Minor relapse in the nose occurred in two cases. No adverse events or major infections were noted.<\/jats:p><jats:p><jats:bold>Conclusion.\u2002<\/jats:bold> RIT seems promising and safe in ANCA\u2010positive vasculitis, and controlled studies should be conducted.<\/jats:p>","DOI":"10.1111\/j.1365-2796.2005.01494.x","type":"journal-article","created":{"date-parts":[[2005,5,23]],"date-time":"2005-05-23T07:42:17Z","timestamp":1116834137000},"page":"540-548","source":"Crossref","is-referenced-by-count":190,"title":["Nine patients with anti\u2010neutrophil cytoplasmic antibody\u2010positive vasculitis successfully treated with rituximab"],"prefix":"10.1111","volume":"257","author":[{"given":"P.","family":"ERIKSSON","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,5,23]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02780531"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.10.883"},{"key":"e_1_2_7_5_2","first-page":"99","article-title":"A pilot study of the anti\u2010CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia","volume":"27","author":"Saleh MN","year":"2000","journal-title":"Semin Oncol"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.12.3995"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03078.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10541"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20430"},{"key":"e_1_2_7_10_2","first-page":"9","article-title":"A pilot study of rituximab therapy for refractoy dermatomyositis. 66th meeting of the American college of Rheumatology 2002","volume":"46","author":"Levine T","year":"2002","journal-title":"Arthritis Rheum"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.7.1062-a"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1042\/BST0300824"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008389119525"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370206"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3579(97)80052-0"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020286"},{"key":"e_1_2_7_18_2","first-page":"293","article-title":"Rituximab \u2013 a potential mechanistic\u2010based therapy for treatment of refractory ANCA\u2010associated vasculitis","volume":"26","author":"Keogh KA","year":"2003","journal-title":"Kidney Blood Press Res"},{"key":"e_1_2_7_19_2","first-page":"294","article-title":"B\u2010cell depletion with rituximab for refractory vasculitis","volume":"26","author":"Jayne DRW","year":"2003","journal-title":"Kidney Blood Press Res"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10764"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11181"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.6.2257"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.10.863"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200305000-00011"}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2796.2005.01494.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2796.2005.01494.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T22:28:51Z","timestamp":1697149731000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2796.2005.01494.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,23]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["10.1111\/j.1365-2796.2005.01494.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2796.2005.01494.x","archive":["Portico"],"relation":{},"ISSN":["0954-6820","1365-2796"],"issn-type":[{"value":"0954-6820","type":"print"},{"value":"1365-2796","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,23]]}}}